SosipatrosBoikosMD

Cancer Genetics/Cancer Risk Assessment, Endocrine Cancer, Sarcoma

Medical Oncologist, Co-Leader, Sarcoma Working Group, Washington Hospital Center, Georgetown University Hospital, Georgetown Lombardi Comprehensive Sarcoma Group

Join to view full profile

Dr. Boikos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boikos' full profile

Already have an account?

Office
110 Irving St NW
Washington, DC 20010
Phone+1 240-418-8300

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2008 - 2011
University of Crete School of Health SciencesClass of 2002

Certifications & Licensure

VA State Medical License 2014 - 2026
DC State Medical License 2021 - 2024
MD State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Venetoclax and Irinotecan in Relapsed/Refractory SCLC Start of enrollment: 2021 Jun 30
Withdrawn
Phase 1, Phase 2

Publications & Presentations

PubMed

Genomic Profiling Uncovers a Broader Spectrum of Dermatofibrosarcoma Protuberans: Implications for Diagnosis and Therapy.
Steven Christopher Smith, Kieran Sweeney, Mark G Evans, Kartik Angara, Celia Reynolds
Modern Pathology. 2025-02-14
146 citations
Recurrent epimutation of SDHC in gastrointestinal stromal tumors.
J. Keith Killian, Markku Miettinen, Robert L. Walker, Yonghong Wang, Yuelin Jack Zhu
Science Translational Medicine. 2014-12-24
Thyroid hormone inactivation in gastrointestinal stromal tumors
Sosipatros A. Boikos, Lee J. Helman, Constantine A. Stratakis
The New England Journal of Medicine. 2014-07-03

Journal Articles

The Ewing Family of Tumors Rely on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Steven C Smith, Sosipatros A Boikos, Anthony C Faber, Clinical Cancer Research
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Aaron N Hata, Sosipatros A Boikos, Anthony C Faber, Clinical Cancer Research

Press Mentions

What Is a Sarcoma? Tips for Navigating This Rare Type of CancerFebruary 24th, 2023